Autopsy report · NCT06531395

A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

“Terminated due to strategic business decision.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Kiniksa Pharmaceuticals International, plc

Sponsor type

Industry

Conditions

Sjögrens Disease

Interventions

Abiprubart; Placebo

Participants

3

Sites

16

Countries

United States

Trials that died the same way

• Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
  “Terminated due to business decision” (90% match in meaning)
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
  “Study terminated due to business and strategic decision.” (81% match in meaning)
• Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study
  “terminated due to administrative reasons.” (78% match in meaning)
• A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
  “Terminated prior to completion of accrual per corporate decision.” (76% match in meaning)
• Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
  “Terminated due to the sponsor's decision.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.